Arcus Biosciences, Inc. (RCUS) is a reputable biopharmaceutical company based in Hayward, California. The company is committed to discovering, developing, and commercializing high-potential cancer therapies. RCUS was founded in 2015 by leading scientists in the field of oncology and immunology.
The motivation behind the establishment of Arcus Biosciences was to capitalize on the significant advances in the understanding of immunology and cancer biology to create therapies that can prolong the survival and improve the quality of life of people suffering from various forms of cancer. The company evaluates its developmental candidates from a broader perspective, looking at the potential opportunities and pathways to address cancer effectively.
The company has built an extensive product portfolio of innovative cancer therapies by integrating multiple therapeutic modalities. Its product pipeline includes AB928, an A2a/A2b adenosine receptor antagonist; AB154, an anti-TIGIT antibody; AB680, a small molecule CD73 inhibitor, and AB122, an anti-PD-1 antibody. These product candidates are designed to target beneficial mechanisms in treating cancer, tackling immune evasion, and disrupting the tumor microenvironment.
Arcus Biosciences operates on a highly differentiated, dual strategic model, combining in-house development on key products with major out-/in-licensing agreements. The approach allows Arcus to enhance the value and potential of its pipeline while offsetting some development cost and risk via selective partnering.
The company has developed collaborations with well-known corporate partners. The collaboration with Gilead Sciences is an essential contributor to this effort. In the partnership, the companies work together to co-develop and co-commercialize therapeutic products strategically. The deal with Gilead also enhances the financial strength of Arcus Biosciences, as well as accelerates the development and broadens the scope of its ambitious product portfolio.
Arcus Biosciences is renowned for its scientific rigor, operational excellence, and its approach that focuses on the patient’s needs. With its commitment to pioneering effective cancer therapies, dedicated team, and robust pipeline of promising drugs, the company is making substantial contributions towards revolutionizing the cancer treatment landscape. This effort is reflected in RCUS's steady stock performance, showing potential in the investment market and the company's drive to create a more substantial impact in the future of oncology.
In overall, Arcus Biosciences, Inc. is recognized both for its scientific excellence and its strong commitment to providing innovative solutions that substantially increase the life expectancy and quality of life for cancer patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Arcus Biosciences (RCUS) shares closed at US$24.59, significantly below the average analyst and intrinsic value estimates of $38, suggesting it is undervalued by 35%. This valuation is largely driven by expectations for its kidney cancer pipeline, specifically the HIF-2 alpha inhibitor casdatifan. However, the market assigns a high P/S ratio of 26.8x, indicating substantial expectations for future performance despite the company currently being loss-making.
Arcus Biosciences (RCUS) stock is gaining attention after recent share price movements, closing at US$30.12. Investors are focused on its clinical-stage cancer pipeline, particularly the HIF-2 alpha inhibitor casdatifan, which analysts believe could significantly undervalue the stock at $38. However, despite a positive long-term outlook, its high Price-to-Sales ratio of 32.8x compared to industry averages and potential regulatory risks for its drug pipeline warrant caution.
Arcus Biosciences (RCUS) has seen a strong 200.8% return over the past year, indicating significant investor optimism, partly due to a recent partnership with Summit Therapeutics. However, the stock appears richly valued with a P/S ratio of 33.0x, significantly higher than the biotech industry average, suggesting that much of the optimism is already priced in. The company's valuation framework highlights a wide gap between its current P/S and what its risk profile would typically justify, raising questions about whether future clinical progress can support the current revenue multiple.
Handelsbanken Fonder AB has acquired a new stake worth approximately $1.20 million in Arcus Biosciences, Inc. (NYSE:RCUS) during the second quarter. Institutional investors collectively own 92.89% of the company, and analysts maintain a "Moderate Buy" consensus rating with a $37.80 average price target. The company reported a quarterly loss of $0.72 per share, beating estimates, and revenues of $41 million, which exceeded expectations despite a year-over-year decrease.
Arcus Biosciences reported a significant revenue drop in Q2 2026 to US$41 million from US$160 million a year earlier, alongside a net loss of US$91 million. The company has also cut its full-year 2026 revenue guidance to US$65 million to US$75 million, which analysts believe will require a reconsideration of previous optimistic forecasts. Despite these setbacks, the company's oncology pipeline, particularly casdatifan, and a recent collaboration with Summit Therapeutics remain central to its investment narrative and future revenue potential.